BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21090965)

  • 41. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myeloma: diagnosis complications and supportive care.
    Morgan G
    Hematology; 2012 Apr; 17 Suppl 1():S109-11. PubMed ID: 22507795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathogenesis and treatment of renal failure in multiple myeloma.
    Dimopoulos MA; Kastritis E; Rosinol L; Bladé J; Ludwig H
    Leukemia; 2008 Aug; 22(8):1485-93. PubMed ID: 18528426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnosis and therapy of multiple myeloma.
    Palumbo A; Cerrato C
    Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
    McCarthy PL; Einsele H; Attal M; Giralt S
    Expert Rev Hematol; 2014 Feb; 7(1):55-66. PubMed ID: 24471885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
    Prince HM; Schenkel B; Mileshkin L
    Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817
    [No Abstract]   [Full Text] [Related]  

  • 48. New drugs for multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):592-4. PubMed ID: 17099617
    [No Abstract]   [Full Text] [Related]  

  • 49. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
    Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
    Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
    Terpos E; Dimopoulos MA; Sezer O
    Leukemia; 2007 Sep; 21(9):1875-84. PubMed ID: 17611556
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
    Burke MJ; George E; Adler AI
    Lancet Oncol; 2015 May; 16(5):492-3. PubMed ID: 25818587
    [No Abstract]   [Full Text] [Related]  

  • 52. [Treatment for multiple myeloma: current status and future strategy in Japan].
    Iida S
    Rinsho Ketsueki; 2008 Oct; 49(10):1368-73. PubMed ID: 18833921
    [No Abstract]   [Full Text] [Related]  

  • 53. New developments in post-transplant maintenance treatment of multiple myeloma.
    Liu H; McCarthy P
    Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
    Cavo M
    Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial treatment of transplant candidates with multiple myeloma.
    Moreau P; Touzeau C
    Semin Oncol; 2013 Oct; 40(5):585-91. PubMed ID: 24135403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel therapies in myeloma.
    Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Latest advances and current challenges in the treatment of multiple myeloma.
    Mahindra A; Laubach J; Raje N; Munshi N; Richardson PG; Anderson K
    Nat Rev Clin Oncol; 2012 Feb; 9(3):135-43. PubMed ID: 22349016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of bortezomib on bone health in myeloma: a review of current evidence.
    Zangari M; Terpos E; Zhan F; Tricot G
    Cancer Treat Rev; 2012 Dec; 38(8):968-80. PubMed ID: 22226939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.